Recent Investment Analysts’ Ratings Updates for GSK (GSK)

Several brokerages have updated their recommendations and price targets on shares of GSK (NYSE: GSK) in the last few weeks:

• 9/15/2026 – GSK was given a new $60.00 price target by Berenberg Bank.
• 9/15/2026 – GSK was upgraded by Berenberg Bank from “hold” to “buy”.
• 9/10/2026 – GSK had its “hold” rating reaffirmed by HSBC Holdings plc.
• 9/8/2026 – GSK is now covered by Royal Bank Of Canada. They set a “sector perform” rating on the stock.
• 8/25/2026 – GSK had its “underweight” rating reaffirmed by Morgan Stanley.
• 8/1/2026 – GSK was downgraded by Wall Street Zen from “buy” to “hold”.
• 7/30/2026 – GSK had its “hold” rating reaffirmed by Deutsche Bank Aktiengesellschaft.
• 7/29/2026 – GSK was downgraded by Weiss Ratings from “buy (b-)” to “hold (c+)”.
• 7/24/2026 – GSK is now covered by Citigroup Inc.. They set a “neutral” rating on the stock.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 8th. Stockholders of record on Friday, August 14th will be given a dividend of $0.4515 per share. This is a boost from GSK’s previous quarterly dividend of $0.44. This represents a $1.81 annualized dividend and a dividend yield of 3.6%. The ex-dividend date of this dividend is Friday, August 14th. GSK’s dividend payout ratio is currently 55.63%.

GSK plc is a global biopharmaceutical company headquartered in Brentford, England. The company researches, develops and manufactures medicines and vaccines for the prevention and treatment of disease, serving patients and healthcare providers in markets around the world.

GSK focuses on specialty medicines and vaccines in areas including infectious diseases, HIV, respiratory disease, immunology and oncology. Its products include prescription medicines, long-acting treatments and vaccines designed to protect against diseases such as shingles, meningitis, influenza and respiratory syncytial virus (RSV).

The company was formed in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham.